98%
921
2 minutes
20
Histopathological differentiation in pediatric adrenocortical carcinoma (pACC) is difficult and clinical prediction and stratification scores are not evaluated yet. Therefore, this review aims to summarize current evidence on the value and accuracy of the two commonly used scoring systems (Weiss/Armed Forces Institute of Pathology (AFIP)) pACC. On this base, one might be able to evaluate if patients may benefit from a unique scoring system. For this, we performed a systematic review of the published literature and included 128 patients in our analysis. The majority (72%) of the pACCs had a good clinical course. The follow-up time ranged from 0 to 420 months with a mean age of 5.6 years at diagnosis. Patients with a good clinical course were younger (mean 4.8 years) than patients with a poor outcome (mean 7.6 years). Comparing the two scoring systems, the specificity of the Weiss score was very low (25%), whereas the sensitivity was 100%. According to the AFIP score, specificity (77%) was higher than the Weiss score, whereas the sensitivity of the AFIP score was minimal lower with 92%. Age differences were recognizable as the specificity was lower in infants <4 years (20%) than in older children (32%). In contrast, the specificity of the AFIP score was higher in infants <4 years (82%) than in older age groups (76%). Summarizing our results, we could show that the Weiss score is not a suitable tool for the prediction of malignancy in pACC in comparison with the AFIP score, but further efforts may seek to ensure early and accurate stratification through augmented scoring.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1530/ERC-22-0259 | DOI Listing |
JAMA Neurol
September 2025
Translational Neuropathology Research Laboratory, Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia.
Importance: Exposure to fine particulate matter air pollution (PM2.5) may increase risk for dementia. It is unknown whether this association is mediated by dementia-related neuropathologic change found at autopsy.
View Article and Find Full Text PDFDiabetes Ther
September 2025
HaaPACS GmbH, Schriesheim, Germany.
Introduction: Weight and diabetes stigma among healthcare professionals (HCPs) may negatively impact treatment decisions, patient outcomes, and physician-patient interactions. We assessed the relationship between weight stigma, diabetes stigma, perceptions of healthcare quality, and avoidance of healthcare among adults with type 2 diabetes (T2D).
Methods: This observational, online survey-based study included 857 US adults with T2D.
Brain
September 2025
IRCCS Istituto delle Scienze Neurologiche di Bologna, UOC Clinica Neurologica, Bologna, 40139, Italy.
An early diagnosis of Parkinson's disease (PD) represents a challenge and novel accurate biomarkers are therefore urgently needed. Detection of phosphorylated α-synuclein (p-α-syn) in skin nerve fibers has shown promise as such a marker. However, its accuracy for the identification of PD among patients with early signs of parkinsonism has not been thoroughly explored.
View Article and Find Full Text PDFInt J Surg
September 2025
Endoscopy Center and Endoscopy Research Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
Background And Aims: A scoring model was proposed to support endoscopic decision-making for cardial submucosal tumors (SMTs). The aim of this study is to perform a multicenter validation of the clinical scoring model and to introduce a new clinical classification system for cardial SMTs.
Methods: A multicenter analysis of endoscopic decision-making for cardial submucosal tumors (SMTs) was conducted.
J Viral Hepat
October 2025
Technion Israel Institute of Technology, Rappaport Faculty of Medicine, Haifa, Israel.
The coexistence of chronic hepatitis B (CHB) and metabolic dysfunction-associated liver disease (MASLD) gained recognition, but the diagnostic performance of non-invasive markers regarding it remains underexplored. This study aimed to evaluate the utility of the FIB-4 index for fibrosis prediction in CHB patients and investigate its performance in the distinct subgroup of CHB-MASLD. A prospective study from 2021 to 2022 included 109 CHB and 64 CHB-MASLD patients.
View Article and Find Full Text PDF